Peptide Graded

Enfuvirtide

Is Enfuvirtide safe?

Trial safety data, near-universal site reactions

AStrong human evidenceFDA approvedas of 2026-10-26

Injection-site reactions were close to universal. In TORO 1, 98% of enfuvirtide patients had pain, redness, nodules or cysts at injection sites. About 4% stopped treatment because of them. The trials also found a higher rate of bacterial pneumonia in the enfuvirtide arm, which the label flagged. Rare hypersensitivity reactions also occurred. Diarrhea, nausea and fatigue were otherwise similar to controls. 12

Injection-site reactions in 98% of patients, a modestly higher rate of bacterial pneumonia, and rare hypersensitivity. Body-wide side effects were otherwise similar to background therapy alone. 12

Read the full Enfuvirtide page

More on Enfuvirtide

Citations

  1. Lalezari 2003, NEJM: enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America (TORO 1) doi.org
  2. Genentech 2024: statement on discontinuation of Fuzeon (enfuvirtide) in the US gene.com

Reference information only, not medical advice. Drawn from the Enfuvirtide article, fact-checked against the cited sources. No dosing anywhere on this site.